Abiraterone acetate is a lyase inhibitor (CYP 17 inhibitor) able to hinder androgen biosynthesis; it was approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of mCRPC, also in first line. 2 Enzalutamide is a second-generation nonsteroidal AR inhibitor that, thanks to its higher affinity, reduces the nuclear translocation of AR by impairing DNA binding to androgen response elements (AREs). been analyzed as prognostic biomarker 4 and has been hypothesized to be used as predictive biomarker of response to ADT. 5 Among several alternative splicing variants of AR gene, AR-V7 is the most prevalent and biologically relevant. 6 Recently different authors correlated the circulating tumor cells (CTC) AR-V7 expression with the lack of benefit by hormonal therapies as abiraterone and enzalutamide 7, 8 and the increase of sensitivity to taxane based therapies. 9 However, two aspects affect the role of AR-V7 as a biomarker in castration resistant prostate cancer patients: first of all the modality of detection, second its association to hormone therapy sensitivity. Because of extreme heterogeneity of prostate cancer, CTC population seems to be the best compartment for investigation of AR-V7 status. 5, 10 CTC number per mL of blood is considered prognostic per se and previous studies showed that AR-V7 detected in CTC resulted an independent prognostic biomarker. 11 The number of circulating biomarker assays based on reversetranscription quantitative PCR (RT-qPCR) technology is increasing. thawing and using QC-0 directly in the laboratory of production and (ii) sending them to the user laboratory IRCCS Istituto Tumori of Bari); dryice transportation & storage at −80°C followed step by step the institutional procedure scheduled for diagnostic reagents provisioning, so representing a routinely applicable scheme.
A "CTC-AR-V7-QCs application SOPs" describing how to obtain two more standard aliquots, QC-1 and QC-2, was edited: for testing, all 500 μL of CTC-AR-V7-QC-0 and a first CTC-AR-V7-QC-1 (QC-1)
were used, and a second CTC-AR-V7-QC-2 (QC-2) control level was created diluting 400 and 100 μL, respectively in 15 mL polypropylene falcon filled with 4.9 mL 1× sterile PBS. The QC-0, QC-1, and QC-2
Quality Control vials were processed with the same protocol of 5 mL of blood from patients.
cDNA from CTC-AR-V7 Cell based Reference sample, obtained with
Qiagen kit (Germany; CE-marked) and 2100 bioanalyzer analysis was 
| CTC enrichment and mRNA study
Blood was collected in 5 mL EDTA tubes and immediately analyzed or stored at 4°C for 24 h maximum. CTC isolation and enrichment had been already described by Antonarakis et al. 11 Briefly CTC were enriched using the Adna Test Prostate Cancer Select kit (Qiagen, Germany; CE-marked) following the manufacturer's protocol. The test based on the ability to magnetically separate CTC cells using antibodies against epithelial and tumor associated antigens. Cell lysate was immediately used or stored at −20°C until 1 week. mRNA has been obtained from cell lysate using the Adna Test Prostate Cancer Detect kit (Qiagen, Germany) following the manufacturer's protocol and was completely retrotranscribed by the SensiScript RT kit (Qiagen). cDNA was used as a template in a multiplex PCR reaction useful to amplify two tumor associated antigens mRNA: PSA (prostate specific antigen) and PMSA (prostate specific membrane antigen) and an endogenous reference mRNA, beta-actin. The amplified PCR products were evaluated by Bioanalyzer electrophoresis (Agilent).
Session by session, as a full control of assays efficiency, all samples were processed simultaneously to the CTC-AR-V7 Cell based Reference sample.
The amplified PCR products were used to detect AR full length (AR-FL; NM_000044) and AR-V7 (NM_001348061.1) splicing variant. Multiplex Real Time PCR method for AR-FL, AR-V7, and Actin detection was coupled to the "Multiplex Qt expression of AR isoforms" analysis, the file was edited to have free space for PCR parameters including Ct, and to give the user Actin and AR isoforms copies/mL of patient blood. A color-code signal also gave indication of AR isoforms presence at higher or lower level respect to the assay Limit of Quantification (10 copies/mL of blood). So, at the end of the full process, the ARV7 "positive/negative" validated result was obtained for all samples. When both AR isoforms were detected over this limit of quantification, the derived AR-V7 versus AR-FL ratio was also obtained. Median follow-up was 20.5 months.
| Patients

| Statistical analysis
To compare log-rank tests, Kaplan-Meier curves were performed through the use of "survival" and "survminer" R packages. R version was 3.4.2 3 | RESULTS
| Verification of multiplex qPCR
The kit ability to address the requirement has been verified to confirm the declared quantification and detection limits (LOQ/D) of 10 copies/ reaction. The LOQ/D is the lowest target concentration that can be precisely detected and that can be reliably distinguished from "analytical noise" in at least 95% of reactions. Supplementary Table S1 reports the intra-assay and inter-assay results. progressively, to be able to evaluate consequently the performances.
The study of stability was executed over 6 and 10 months.
Notably the results showed how the efficiency of cell/mRNA recovery did not change significantly in the first 6 months whereas a difference between 0 and 10 months was detected (Table 1) .
Despite this difference, AR-V7 versus AR-FL ratio have a minimal change ( Figure 2 ). In particular, the results showed no significant ARs change copies and ratio (P-value >0.2231) between 1 versus 6 months. On the contrary, 1 versus 10 months change was significant for both ARs copies and ratio (P-value >0.0105) but at a very low ratio value (inferior to 1%, coming from 2.01% to 1.38%, shown in Figure 2 ).
To test robustness in the real life, we also evaluated the effect of shipping & storage planning multiple session of shipping (5) that allowed seven independent tests (four tests at 6 months and three tests at 10 months) in Bari IRCCS user laboratory. Shipment and delivery respected step by step the institutional procedure followed by usual diagnostic kits providing. As shown in Table 2 , the results revealed a similar decrease of 80% and 86% of copies, respectively, for AR-FL and AR-V7 isoforms. Notably, no significant differences were seen in AR-V7 versus AR-FL ratio ( Figure 3 ). Together, values of AR-FL and AR-V7 copies and ratio could be applied using a qualitative reference range for good performances monitoring of the assay. 
| Clinical meaning in laboratory report
We generated a typical diagnostic report in format and presentation, We also generated a Molecular Diagnostics Request Format for AR-V7 test indicating anamnestic and pathological (stage, Gleason grade, etc.) information of patient, the current type of therapy, the modality of sample collection, conservation, and transportation specifics.
| Clinical setting evaluation
Our cohort included 44 patients whose characteristics are reported in Table 3 . This series of patients had been used to validate clinically our Copies/μL data (n = 26) from QC-1 + QC-2 were mathematically normalized to QC-0 by proportional multiplication for the dilution coefficient. Copies/μL data from QC-1 + QC-2 were mathematically normalized to QC-0 by proportional multiplication for the dilution coefficient. patients had been considered for further analyses. Overall PSA response rate, defined as PSA reduction ≥50% from the baseline, was respectively 33%, 44%, and 28% in patients treated with abiraterone/ enzalutamide/ormono and chemotherapy. When considering the presence of AR-V7 in the overall series and in patients treated with abiraterone or enzalutamide in first line, in both cases there was an inverse relationship between PSA reduction and AR-V7 presence. In particular, only three patients, positive for AR-V7 had PSA reduction ≥50%, while 72.7% of AR-V7 patients had no PSA response both considering the overall series ( Figure 5A ) and the patients specifically treated with abiraterone/enzalutamide ( Figure 5B ).
Moreover, 75% (6/8) AR-V7+ patients were hormone-resistant to abiraterone/enzalutamide treatment, while 57% (8/14) AR-V7− patients were hormone sensitive, even if no statistical significance had been reached, due to the small size of the cohort ( Figure 6 ).
Overall survival could not be evaluated due to the lack of a reasonable number of events, which would have made possible OSrelated survival analysis. In the overall cohort median PFS was 6 months (95% CI, 7 to NA) in AR-V7+ patients and 18 months (95% CI, 7 to NA) in AR-V7− patients (P = 0.054) ( Figure 7 ).
| DISCUSSION
The prognostic role of AR-V7 variant is strictly associated to 
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FIGURE 6
Hormone sensitive (blu square) and hormone resistant (red square) patients distributed with respect to AR-V7 status: 0, absence of AR-V7; 1, presentce of AR-V7. 75% AR-V7+ patients were hormono-resistant to abiraterone/enzalutamide treatment while 57% AR-V7− patients, even if with no statistical significance due to the small size of the cohort FIGURE 7 Kaplan-Meier curves related to PFS of the overall series: AR-V7+ patients (blu line) had a poor PFS (P = 0.054). Red line: AR-V7− patients
